Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
|Articles|April 22, 2015
Single-Use Mixers Improve Ergonomics
New HyPerforma Single-Use Mixers from Thermo Scientific address user requirements.
The Thermo Scientific HyPerforma Single-Use Mixers (SUM) combine the benefits of its widely used SUMs with advancements that address the requirements of single-use bioprocessors from scale-up to cGMP manufacturing. New features include optimized tubing management, advanced clean-in-place sterilization, rapid set-up and turn-around times, and streamlined handling of hazardous materials.
“The need to maximize efficiency is an ongoing requirement and we redesigned our HyPerforma SUM with many of the same ergonomic benefits introduced last year in our HyPerforma single-user bioreactor, including ergonomic enhancements such as handles for enhanced system mobility,” said Jacob McNeil, senior product manager for single-use systems at Thermo Fisher Scientific.
The new HyPerforma range now provides six capacity options (50, 100, 200, 500, 1000 and 2000 L) to address customer demand for an even smaller footprint, simplified set-up and cleaning, and easy loading of bioprocess containers. Sight windows and level indicators were incorporated so end-users can better assess fill levels. Additional features include easy-to-manage tubing systems, adjustable height Powdertainer hangers, rapid heat-up and cool-down times, and cable-management trees.
Source:
Related to this article
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.